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Background/aim: There are not many studies conducted to detect and recognize the symptoms during the prediabetes period. In our
study, we aimed to determine the symptoms that can be seen in prediabetes and diabetes and their prevalence and to determine the
similarities and differences between the two groups.
Materials and methods: Individuals who were diagnosed with prediabetes or diabetes, over the age of 18, literate, and accepted to
collaborate were included in our study. The “Diabetes Symptoms Checklist Scale” was used by interviewing 321 participants, 161
prediabetic and 160 diabetic, face-to-face.
Results: It has been found that the most common symptom in both the prediabetes and the diabetes group is “fatigue” (88.2% prediabetes,
89.4% diabetes). The symptoms seen in the dimensions of neurology and hyperglycemia are more common in individuals with diabetes
than in individuals with prediabetes [neurology score: 1.85 ± 0.84 vs. 1.66 ± 0.64 (p = 0.02), respectively; hyperglycemia score: 2.39 ±
0.94 vs. 2.08 ± 0.83 (p = 0.002), respectively]. It was observed that the symptom burden increased in all subdimensions with the long
duration of illness, being a female, not working, having a family history, and not doing exercise, and high fasting blood glucose and
high HbA1c values. The level of education, family history, accompanying hyperlipidemia, neurology, and hyperglycemia symptoms are
associated with diabetes; and it has been determined that cardiology symptoms are associated with prediabetes.
Conclusion: Especially; during the follow-up of patients with prediabetes who have a low education level and diabetic family history
and concomitant hyperlipidemia, there may be an increase in neurological and hyperglycemic symptoms at the point of development of
type 2 diabetes. In this respect, we recommend that these factors, which we found to be predictive of diabetes compared to prediabetes,
should be questioned more carefully during patient visits.
Key words: Diabetes symptoms checklist scale, prediabetes, symptom, type 2 diabetes mellitus

1. Introduction
The concept of prediabetes includes individuals who
do not meet the sufficient criteria for a diagnosis
of diabetes, but whose blood sugar is above normal
limits. Prediabetes is an important risk factor for the
development of type 2 diabetes mellitus (T2DM). In
addition, the complication rate of 10%–40% in newly
diagnosed T2DM patients at the time of diagnosis
and the fact that macrovascular and microvascular
complications associated with T2DM can start to
develop from the prediabetes period indicate that
this prediabetic period is not a quiet and innocent
period [1]. Therefore, the ability to prevent or delay
the development of T2DM and diabetes-related

complications with early diagnosis increases the clinical
importance of prediabetes diagnosis.
There are many symptoms seen during the natural
course of prediabetes and T2DM disease and as a result
of the complications they cause. Symptoms vary greatly
from person to person and are influenced by many
factors. While some of these symptoms are more specific
to the disease, some symptoms may be nonspecific.
Especially in the early period, more nonspecific and
subtle symptoms can be encountered. In addition, there
is not enough research and clear data on which diabetes
symptoms are seen and how often they are encountered
during the prediabetes period. All of these can cause
delays in the diagnosis of diabetes.

* Correspondence: muratdagdeviren61@hotmail.com
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In our study, we aimed to identify common symptoms
in prediabetes and T2DM patients, compare these two
periods in terms of symptom characteristics, and thus
obtain new data that can guide the diagnosis of prediabetes
and diabetes in an earlier period in clinical practice.
2. Materials and methods
2.1. Study protocol and sampling
The study is an analytical, cross-sectional study conducted
between June 25, 2020–July 31, 2020. According to
the power analysis, a minimum of 150 patients with
prediabetes diagnoses and 150 patients with T2DM
diagnoses were planned to be included in the study.
Our study was conducted with the approval of the local
ethics committee (2012-KAEK-15/2124). The study was
carried out in accordance with the Helsinki Declaration
and verbal and written consent was obtained from all
participants.
T2DM and prediabetes patients diagnosed according
to the American Diabetes Association (ADA) criteria and
under follow-up were included in the study [2]. T2DM
diagnosis; HbA1c ≥ 6.5% or fasting plasma glucose ≥126
mg/dL or 2nd-h glucose value ≥200 mg/dL in the oral
glucose tolerance test or random plasma glucose ≥200 mg/
dL with classical hyperglycemia symptoms was determined
by the presence of at least one of the criteria. Prediabetes
diagnosis; HbA1c 5.7%–6.4% or fasting plasma glucose
100-125 mg/dL or 2nd-h glucose value 140–199 mg/dL in
the oral glucose tolerance test by the presence of at least
one of the criteria [2]. During the study period, a total of
422 T2DM and prediabetes diagnosed individuals who
applied to the clinics where the study was conducted were
evaluated, and 321 adult participants, who were literate,
had no psychiatric disability, and had accessible laboratory
data, were included in the study. Patients with acute
illness and Covid 19 infection in the last 2 weeks were not
included in the study (Figure).
After obtaining verbal and written informed consent
from the patients who accepted to participate in the study
and met the current criteria, the following questionnaire
forms were applied in an appropriate polyclinic room by
face-to-face interview.
Participants’ age, gender, marital status, education
level, occupation, monthly income level, employment
status, how long they have been diagnosed with diabetes or
prediabetes, family history, additional diseases, medications
used for treatment, compliance with treatment, smoking
and alcohol use, exercise and diet status, regular medical
control status, current laboratory values and the presence
of a chronic complication were evaluated with a case
report form consisting of 19 items. Fasting blood glucose
and HbA1c values of the patients were recorded from the
hospital automation system and patient files.
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The symptoms of the participants were evaluated
with the Diabetes Symptoms Checklist Scale, which was
developed by Grootenhuis et al. in 1994 and the validity
and reliability study in Turkish was conducted by Terkeş
and Bektaş in 2012 [3].
Diabetes Symptoms Checklist Scale is a Likert-type
scale consisting of 33 questions with answer options
ranging from 1 to 5 such as “none”, “a little”, “moderate”,
“very”, “excessive”. It includes six subdimensions:
neurology, psychology/fatigue, cardiology, ophthalmology,
psychology/cognitive, and hyperglycemia.
2.2. Statistical analysis
The data obtained were analyzed with IBM SPSS 22.0
(IBM Corp. Released 2013. IBM SPSS Statistics for
Windows, Version 22.0. Armonk, NY: IBM Corp.)
program. Categorical data were expressed as numbers
and percentages. The normal distribution of the data
was examined with the Kolmogorov-Smirnov test and
histogram, and since the data were normally distributed,
they were expressed as mean and standard deviation. The
student t-test was used to compare the normal distributed
continuous data between two groups. Cronbach Alpha
test was used to test the reliability of the applied scale
data. Pearson’s correlation test was used for correlation
analysis. Logistic regression analysis modeling was
performed to predict diabetes risk according to
prediabetes. Hosmer & Lemeshow test was performed in
terms of model fit. A value of p < 0.05 was accepted for
statistical significance.
3. Results
Two hundred and fifty-eight (80.35%) of the participants
in the study are women; 63 of them (19.65%) were male.
The average age was 56.1 (min: 29, max: 90). Age, gender,
marital status, education level, employment status,
occupation, monthly income, smoking and alcohol use,
exercise, and diet status were similar between the two
groups. When both groups were examined in terms of
chronic diseases, it was found that hypertension, heart
disease, and hyperlipidemia were significantly higher in
the diabetes group compared to the prediabetes group
(Table 1).
While 101 patients (62.7%) in the prediabetic group
had a family history, 118 individuals (73.8%) in the
diabetes patient group had a family history (p = 0.03).
When the two groups were compared in terms of disease
duration; the mean duration of illness was significantly
higher in the diabetes group compared to the prediabetes
group (113.57 months, 31.34 months, respectively; p <
0.001), while the patients with poor compliance with
treatment were in the majority (48.7%) in the prediabetes
group, those in the diabetes group were in the majority
(42.5%) (Table 2).
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Table 1. General demographic characteristics of the study group.
Prediabetes
(n = 161)

Type 2 DM
(n = 160)

p

55.2 ± 11.71

57.06 ± 9.81

>0.05*

Female

134 (83.2)

124 (77.5)

Male

27 (16.8)

36 (22.5)

Age – year
Gender – n (%)

>0.05‡

Marital status – n (%)

>0.05‡

Nonmarried

36 (22.4)

35 (21.9)

Married

125 (77.6)

125 (78.1)

Level of education– n (%)

>0.05‡

Mid-school and lower

130 (80.7)

126 (78.8)

High School

19 (11.8)

29 (18.1)

University and higher

12 (7.5)

5 (3.1)

Employment Status – n (%)

>0.05‡

Unemployed

143 (88.8)

139 (86.9)

Full-time employed

18 (11.2)

21 (13.1)

Officer

5 (3.1)

7 (4.4)

Worker

5 (3.1)

5 (3.1)

Self-employed

5 (3.1)

11 (6.9)

House wife

121 (75.2)

112 (70)

Retired

20 (12.4)

23 (14.4)

Other

5 (3.1)

2 (1.3)

Below minimum wage

35 (21.7)

45 (28.2)

Minimum wage

43 (26.7)

46 (28.7)

2500–5000 TL

70 (43.5)

53 (33.1)

5000 TL and higher

13 (8.1)

16 (10)

Occupancy – n (%)

>0.05‡

Monthly income – n (%)

>0.05‡

Smoking – n (%)

>0.05‡

Nonsmoker

143 (88.8)

134 (83.8)

Smoker

18 (11.2)

26 (16.2)

Alcohol – n (%)

>0.05‡

Nondrinker

159 (98.8)

157 (98.1)

Drinker

2 (1.2)

3 (1.9)

Nondoing

127 (78.9)

123 (76.9)

Doing

34 (21.1)

37 (23.1)

Diet – n (%)

>0.05‡

Exercise– n (%)

>0.05‡

None

92 (57.1)

109 (68.1)

Irregular

46 (28.6)

34 (21.3)

Regular

23 (14.3)

17 (10.6)

Chronic disease history – n (%)
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Table 1. (Continued).
Hypertension

74 (46)

92 (57.5)

0.04‡

Cardiovascular disease

17 (10.6)

31 (19.4)

0.03‡

Obesity

24 (14.9)

37 (23.1)

>0.05‡

Kidney disease

4 (2.5)

5 (3.1)

>0.05‡

Thyroid disease

34 (21.1)

30 (18.8)

>0.05‡

Hyperlipidemia

30 (18.6)

64 (40)

<0.001‡

Neurological disease

7 (4.3)

1 (0.6)

Psychiatric disease

4 (2.5)

6 (3.8)

>0.05‡

Ophthalmological disease

35 (21.7)

44 (27.5)

>0.05‡

Chest disease

23 (14.3)

31 (19.4)

>0.05‡

Other chronic diseases

20 (12.4)

9 (5.6)

0.03‡

Abbreviations; TL: Turkish lira, DM: Diabetes Mellitus
* Student’s t-test was used.
‡ Pearson’s chi-square/Fisher’s exact test was used.

Table 2. Comparison of study groups’ data on primary diseases.
Prediabetes
(n = 161)

Type 2 DM
(n=160)

p

Type 2 DM family story – n (%)

101 (62.7)

118 (73.8)

0.03‡

Duration of illness – month

31.34 ± 40.82

113.57 ± 87.25

<0.001*

Periodic medical check – n (%)

>0.05‡

No

70 (43.5)

84 (52.5)

Yes

91 (56.5)

76 (47.5)

Noninsulin Antidiabetic agent

44 (27.3)

142 (88.8)

Insulin

0

30 (18.8)

Poor

78 (48.4)

41 (25.6)

Medium

44 (27.3)

51 (31.9)

Good

39 (24.2)

68 (42.5)

Cardiovascular diseases

0

4 (2.5)

Diabetic foot

0

3 (1.9)

Retinopathy

1 (0.6)

19 (11.9)

Neuropathy

0

9 (5.6)

Nephropathy

0

7 (4.4)

Fasting blood glucose– mg/dL

101.34 ± 9.72

157.73 ± 53.99

<0.001*

HbA1c – %

5.81 ± 0.40

7.92 ± 1.73

<0.001*

Drug usage – n (%)
<0.001‡
<0.001‡

Treatment compliance– n (%)

Complications of diabetes– n (%)

Abbreviations; DM: Diabetes Mellitus, HbA1c: Hemoglobin A1c
‡ Pearson’s chi-square/Fisher’s exact test was used.
* Student’s t-test was used.
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Figure. Determination of patient groups.

When two groups are examined in terms of
complications; while 1 patient in the prediabetes group
had retinopathy (0.6%), 19 patients (11.9%) in the
diabetes group had retinopathy (p < 0.001). Other
complications were only present in the diabetes group
(Table 2).
Considering the laboratory values; fasting blood
glucose and HbA1c values were statistically significantly
higher in the diabetes group (p < 0.001) (Table 2).
Considering the application results of the Diabetes
Symptoms Checklist Scale; it was observed that the
symptom that the patients experienced in both groups at
the highest rate (88.2% of those with prediabetes, 89.4%
of those with diabetes) was “fatigue” at any level (a little,
moderate, very, excessive).
When the two groups were compared in terms of
symptoms; it was found that the symptom of “difficulty in
concentrating on a subject” was observed at a higher rate
in individuals with prediabetes than in individuals with
diabetes (54% and 42.5%) (p = 0.04). The diabetes group
was found to be more symptomatic than the prediabetes
group in terms of “the need to urinate frequently” and
“burning pain in the legs during the day” symptoms (p
< 0.001 and p = 0.03, respectively). The rates of other
symptoms were similar between the two groups (p > 0.05)
(Table 3).
When the data are analyzed at the level of the
subdimensions of the scale; it was found that there was a
statistically significant difference only in the scores obtained
from the neurology and hyperglycemia subdimensions
between the two groups. Individuals with prediabetes
had a score of 1.66 ± 0.64 in the neurology subdimension,
while the score of individuals with diabetes was 1.85 ±
0.84 (p = 0.02). In the hyperglycemia subdimension, the
average score of individuals with prediabetes was 2.08 ±
0.83, while the average score of individuals with diabetes
was 2.39 ± 0.94 (p = 0.002) (Table 4).

As the duration of illness, fasting blood glucose and
HbA1c values increase; it was observed that symptom
scores increased in all subdimensions (Table 5).
Education level, presence of family history,
accompanying hyperlipidemia, neurology, and symptoms
of hyperglycemia were determined as associated factors
for type 2 diabetes as compared to prediabetes; cardiology
symptoms were found to be associated with prediabetes as
compared to diabetes (Table 6).
4. Discussion
In our study, it has been found that the most common
symptom in both the prediabetes group and the diabetes
group is “fatigue”, and the symptoms seen in the
dimensions of neurology and hyperglycemia are more
common in individuals with diabetes than in individuals
with prediabetes. It was observed that the symptom
burden increased in all subdimensions with the long
duration of illness, being a female, not working, having a
family history, not doing exercise, and high fasting blood
glucose and high HbA1c values. The level of education,
family history, accompanying hyperlipidemia, neurology,
and hyperglycemia symptoms are associated with diabetes;
and it has been determined that cardiology symptoms are
associated with prediabetes.
Prediabetes is an important risk factor for
macrovascular complications, especially cardiovascular
disease [4]. Prediabetes is also an important risk factor for
microvascular complications, and diabetic retinopathy,
nephropathy, and neuropathy have also been detected in
individuals with prediabetes [5–7]. In addition, autonomic
dysfunctions such as bradycardia and erectile dysfunction
have been found to be associated with prediabetes [8].
In the light of this information available in the literature,
it was a result that we expected to find similar symptom
burdens in prediabetes and diabetes groups. In our study,
only symptoms related to neurology and hyperglycemia
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Table 3. Comparison of the groups in terms of the frequency of symptoms*.
Prediabetes
(n = 161)

Type 2 DM
(n = 160)

p‡

1. Fatigue

142 (88.2)

143 (89.4)

>0.05

2. Pain in the calves when walking

94 (58.4)

100 (62.5)

>0.05

3. Numbness (loss of sensation) in the feet

58 (36)

67 (41.9)

>0.05

4. A general feeling of exhaustion/exhaustion

124 (77)

121 (75.6)

>0.05

5. Shortness of breath at night

33 (20.5)

35 (21.9)

>0.05

6. Drowsiness or dizziness

96 (59.6)

103 (64.4)

>0.05

7. Difficulty concentrating on a subject

87 (54)

68 (42.5)

0.04

8. Emotional changes

127 (78.9)

123 (76.9)

>0.05

9. Numbness in the hands (loss of sensation)

96 (59.6)

80 (50)

>0.05

10. Blurred vision that does not go away even when wearing glasses 54 (33.5)

57 (35.6)

>0.05

11. Tingling in arms and legs at night

63 (39.1)

74 (46.3)

>0.05

12. Excessive thirst

72 (44.7)

87 (54.4)

>0.05

13. Palpitations

64 (39.8)

64 (40)

>0.05

14. Impaired vision

76 (47.2)

70 (43.8)

>0.05

15. Burning pain in the calves at night

89 (55.3)

93 (58.1)

>0.05

16. Dry mouth

111 (68.9)

124 (77.5)

>0.05

17. Increased fatigue during the day

104 (64.6)

104 (65)

>0.05

18. Lightning flashes or black spots in the field of vision

93 (57.8)

97 (60.6)

>0.05

19. Anger before eating

55 (34.2)

63 (39.4)

>0.05

20. Feeling exhausted when woke up in the morning

109 (67.7)

111 (69.4)

>0.05

21. Sudden stinging pain in the legs under the knee and feet

54 (33.5)

59 (36.9)

>0.05

22. Sometimes clear, sometimes blurred vision

90 (55.9)

86 (53.8)

>0.05

23. The need to urinate frequently

93 (57.8)

121 (75.6)

0.001

24. Pain in the chest or heart area

58 (36)

67 (41.9)

>0.05

25. Burning pain in the legs during the day

44 (27.3)

62 (38.8)

0.03

26. Tingling sensation and numbness in hands or fingers

92 (57.1)

85 (53.1)

>0.05

27. Get angry quickly

114 (70.8)

110 (68.8)

>0.05

28. Sudden deterioration in vision

33 (20.5)

30 (18.8)

>0.05

29. A different feeling in the feet and legs below the knee when
touched

50 (31.1)

51 (31.9)

>0.05

30. Difficulty breathing during physical activity

90 (55.9)

85 (53.1)

>0.05

31. Feeling dizzy in the head (difficulty in thinking clearly)

84 (52.2)

78 (48.8)

>0.05

32. Drinking too much liquid (all kinds of drinks)

74 (46)

91 (56.9)

>0.05

33. Difficulty in concentrating

79 (49.1)

66 (41.3)

>0.05

34. Tingling sensation and numbness in the area of the legs below
the knee and in the feet

64 (39.8)

60 (37.5)

>0.05

* The rates of prediabetes and diabetes group responding to the scale questions as “a little”, “moderate”, “very”, or
“excessive” are shown.
Abbreviations; DM: Diabetes Mellitus
‡ Pearson’s chi-square/Fisher’s exact test was used.
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Table 4. Comparison of subdimensions with which questions are grouped. *
Prediabetes
(n = 161)

Type 2 DM
(n = 160)

Cronbach’s Alpha

p‡

Psychology (exhaustion)

2.29 ± 0.79

2.33 ± 0.84

0.81

>0.05

Psychology (cognitive)

1.86 ± 0.68

1.86 ± 0.67

0.68

>0.05

Neurology

1.66 ± 0.64

1.85 ± 0.84

0.79

0.02

Cardiology

1.75 ± 0.55

1.73 ± 0.57

0.77

>0.05

Ophthalmology

1.49 ± 0.53

1.54 ± 0.66

0.81

>0.05

Hyperglycemia

2.08 ± 0.83

2.39 ± 0.94

0.71

0.002

Abbreviations; DM: Diabetes Mellitus
* Points; it was calculated by dividing the total scores of the answers given to the questions in the relevant subdimension by the
number of questions in the subdimension.
‡ Student’s t-test was used.
Table 5. Correlation analysis between demographic data and subdimension symptoms in the whole study group.*
Neurology

Psychology
(exhaustion)

Psychology
(cognitive)

Cardiology

Ophthalmology

Hyperglycemia

r

p

r

p

r

p

r

p

r

p

r

p

FBG

0.21

<0.01

0.06

0.26

0.01

0.90

0.06

0.29

0.17

<0.01

0.24

<0.01

HbA1c

0.24

<0.01

0.09

0.09

0.07

0.24

0.08

0.14

0.20

<0.01

0.22

<0.01

Disease
period

0.34

<0.01

0.19

<0.01

0.12

0.04

0.19

<0.01

0.25

<0.01

0.30

<0.01

Abbreviations; FBG: Fasting blood glucose, HbA1c: Hemoglobin A1c
* Pearson’s correlation test was used.

subdimensions were more common in diabetic patients.
In a study by Adriaanse et al; when individuals with
normal glucose metabolism and diabetic individuals are
compared, it has been reported that diabetic individuals
have higher scores in terms of neuropathic pain, emotional
symptoms, and total symptom burden [9].
In our study, the highest scores in both groups were
obtained from the psychology (fatigue) and hyperglycemia
dimensions. In the study of Terkeş and Bektaş, it was
found that individuals with diabetes experienced the most
neurological and psychological (cognitive) symptoms
[10]. In another study, Kumsar et al. found that individuals
with type 2 diabetes experienced more hyperglycemia and
psychological (fatigue) symptoms, similar to our study
[11]. When the symptoms are examined separately in our
study; it was determined that the most common symptom
experienced by both groups was “fatigue”. In the study
conducted by Kumsar et al. using the same scale, it was
found that diabetic individuals experienced the symptoms
of “get angry quickly”, “need to urinate frequently” and

“fatigue” to an “excessive” degree [11]. In another study by
Adriaanse et al.; “fatigue”, “dry mouth” and “drowsiness or
dizziness” were found to be the most common symptoms
experienced by type 2 diabetes patients [12]. These results
can be explained by the fact that psychology (fatigue)
symptoms are not only seen in glucose metabolism
disorders and can be seen at high levels in the general
population.
In addition, in our study, we found that the increase in
disease duration was associated with increased symptom
burden in all subdimensions. Again, increased HbA1c and
fasting blood glucose values cause an increase in symptoms
in all dimensions. This finding is a finding supported by
many studies including Terkeş’s study and the studies of
Kumsar et al. [3,9,11,13–16].
The positive family history of a patient who is under
follow-up and known to be prediabetic is a risk factor for
the development of type 2 diabetes. This is not a surprising
result because diabetes is a disease with a strong genetic
basis [17]. The fact that a low education level is associated
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Table 6. Logistic regression analysis to investigate independent risk factors predicting diabetes according to
prediabetes.
Risk factor

B (SE)

OR (%95 CI)

p

Age

–0.002 (0.014)

0.99 (0.97–1.03)

>0.05

Gender
Female (RC)
Male

1
0.530 (0.383)

1.7 (0.80–3.60)

>0.05

Level of education
Mid-school and lower (RC)

1

High School

0.885 (0.408)

2.42 (1.09–5.39)

0.03

University and higher

–0.907 (0.701)

0.4 (0.10–1.60)

>0.05

Monthly income
Below minimum wage (RC)

1

Minimum wage

0.114 (0.354)

1.12 (0.56–2.24)

>0.05

2500–5000 TL

–0.442 (0.354)

0.64 (0.32–1.29)

>0.05

0.342 (0.571)

1.41 (0.46–4.31)

>0.05

5000 TL and higher
Family history of type 2 DM
No (RC)
Yes

1
0.640 (0.275)

1.90 (1.11–3.25)

0.02

Exercise
None (RC)

1

Irregular

–0.308 (0.307)

0.74 (0.40–1.34)

>0.05

Regular

–0.414 (0.412)

0.66 (0.30–1.49)

>0.05

Diet
Not doing (RC)
Doing

1
0.085 (0.321)

1.09 (0.58–2.04)

>0.05

Hypertension
No (RC)
Yes

1
0.251 (0.297)

1.29 (0.72–2.30)

>0.05

Obesity
No (RC)
Yes

1
0.190 (0.336)

1.21 (0.63–2.34)

>0.05

Hyperlipidemia
No (RC)

1
1.131 (0.304)

3.10 (1.71–5.62)

<0.001

Psychology (exhaustion)

–0.075 (0.222)

0.93 (0.60–1.43)

>0.05

Psychology (cognitive)

–0.172 (0.230)

0.84 (0.54–1.32)

>0.05

Neurology

0.670 (0.256)

1.95 (1.18–3.23)

0.01

Cardiology

–0.848 (0.381)

0.43 (0.20–0.90)

0.03

Ophthalmology

–0.094 (0.261)

0.91 (0.55–1.52)

>0.05

Hyperglycemia

0.423 (0.164)

1.53 (1.11–2.10)

0.01

Yes

*R2 = 0.23
**Hosmer & Lemeshow test p = 0.42
Abbreviations; SE: Standard Error, OR: Odds Ratio, CI: Confidence Interval, RC: Reference category.
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with an increased risk of type 2 diabetes may be due to the
fact that educated individuals are more conscious, more
knowledgeable about their diseases and their treatments,
and more inclined to read and research. Concomitant
hyperlipidemia is one of the predictors of type 2 diabetes
development because diabetes refers not only to the
defect in carbohydrate metabolism but also to the defect
in fat and protein metabolism [18]. Increased symptoms
in neurology and hyperglycemia subdimensions were
also found to be factors indicating the progression from
prediabetes to type 2 diabetes. One of the most common
microvascular complications of diabetes is neuropathy
[19]. Along with the symptoms caused by neuropathy,
increased hyperglycemic symptoms, which are a result
of impaired glucose metabolism during the transition
from prediabetes to diabetes, may also alert the physician
to the development of diabetes. In this context, detailed
questioning of the neurological and hyperglycemic
symptoms of the patients by the physician may be a guide
in preventing the development of diabetes.
Symptoms in the cardiology subdimension were
associated with prediabetes. This may be due to the
fact that patients with type 2 diabetes are under stricter
cardiological follow-up and are using treatments that
suppress symptoms of the cardiovascular system such
as beta-blockers. In addition, reactive hypoglycemia

symptoms, which can be seen more frequently in the
prediabetes patients, may be confusing with symptoms in
the cardiology subdimension.
Our study is the first study comparing symptoms of
prediabetes and type 2 DM in a wide sociodemographic
data scale in Turkey. But the fact that the study was
conducted during the Covid-19 pandemic process may
have led to a bias in terms of patient application and
symptom evaluation that we could not intervene. In
addition, the inclusion of menopausal women may have
confused menopausal symptoms with other symptoms.
The limitations of our study are that some tests (such as
vitamin D level, and vitamin B12 level) were not performed
in the evaluation of some nonspecific symptoms, only the
patient’s statement was taken into account, and body mass
index was not evaluated.
In the light of all this information, during the
follow-up of patients diagnosed with prediabetes, low
education level, diabetic family history, and concomitant
hyperlipidemia, there may be an increase in neurological
and hyperglycemic symptoms at the point of development
of type 2 diabetes. In this respect, it may be a warning for
the physician to carefully question these factors, which we
found to be predictive of diabetes compared to prediabetes,
during patient visits. However, further studies are needed
to obtain clearer results.
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